Powder: -20°C for 3 years | In solvent: -80°C for 1 year
STF-083010 是一种 IRE1α 核酸内切酶的选择性抑制剂。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 198 | 现货 | ||
5 mg | ¥ 455 | 现货 | ||
10 mg | ¥ 622 | 现货 | ||
25 mg | ¥ 1,050 | 现货 | ||
50 mg | ¥ 1,870 | 现货 | ||
100 mg | ¥ 2,980 | 现货 | ||
200 mg | ¥ 4,530 | 现货 | ||
500 mg | ¥ 6,830 | 待询 | ||
1 mL * 10 mM (in DMSO) | ¥ 490 | 现货 |
产品描述 | STF-083010 is a selective inhibitor of the IRE1α endonuclease. |
体外活性 | WaC3 cells respond to treatments with STF-083010 with gradually decreased growth. In MEC1 and MEC2 cells, STF-083010 produces 20% growth inhibition in 48 hours cultures. In MM.1R MM, MM.1S, and RPMI 8226 cell lines, STF-083010 displays cytostatic and cytotoxic activity in a dose and time-dependent manner. In Eμ-TCL1 CLL cells, STF-083010 displays about 70% growth inhibition after 3 days culture. In SU8686, Panc0403, and MiaPaCa2 cell lines, STF-083010 blocks IRE1α's endonuclease and inhibits XBP1 splicing activity without affecting its kinase activity. |
体内活性 | STF-083010(i.p.,30 mg/kg)在人类多发性骨髓瘤(MM)异种移植模型中显著抑制了肿瘤的生长。 |
激酶实验 | Autophosphorylation activity is measured by adding of 32P-γ ATP. Endonuclease activity is measured by the adding of radiolabeled HAC1 508-nt RNA substrate synthesized in vitro using α32P-UTP. Mix STF083010 with recombinant hIRE1 protein, radiolabeled HAC1 508 nt RNA, and appropriate buffers to incubate. Kinase activity is quantitated by polyacrylamide gel electrophoresis. RNAsecleavage products are quantitated by 32P-γATP or 32P-UTP autoradiography. |
细胞实验 | 3×10E3 (Panc0403, Panc1005, BxPc3, and MiaPaCa2) cell lines are seeded in 96-well plates overnight, and STF-083010(~50 μM) treatment for 48 hours started the next day. |
动物实验 | NOD/SCID/IL2Rγ null mice were injected intraperitoneally of STF-083010(30 mg/kg) dissolved in 16% chremophor. |
别名 | STF083010 |
分子量 | 317.38 |
分子式 | C15H11NO3S2 |
CAS No. | 307543-71-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 31.7 mg/mL (100 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.1508 mL | 15.754 mL | 31.508 mL | 78.7699 mL |
5 mM | 0.6302 mL | 3.1508 mL | 6.3016 mL | 15.754 mL | |
10 mM | 0.3151 mL | 1.5754 mL | 3.1508 mL | 7.877 mL | |
20 mM | 0.1575 mL | 0.7877 mL | 1.5754 mL | 3.9385 mL | |
50 mM | 0.063 mL | 0.3151 mL | 0.6302 mL | 1.5754 mL | |
100 mM | 0.0315 mL | 0.1575 mL | 0.3151 mL | 0.7877 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
STF-083010 307543-71-1 Cell Cycle/Checkpoint IRE1 STF 083010 Inositol requiring enzyme 1 Inhibitor inhibit STF083010 inhibitor